AI Medical Imaging Software Market

Overview

The global AI Medical Imaging Software Market was valued at USD 1.9 billion in 2025 and is projected to reach USD 24.0 billion by 2034, growing at a CAGR of 32.7% during the forecast period (2026–2034). The market is driven by rising imaging volumes, a persistent shortage of radiologists, and a growing body of clinical evidence for AI in stroke, cardiac, breast and lung imaging. The market is shifting from conventional, single-disease algorithms toward foundation-model platforms that detect many findings from one scan, and from research pilots toward reimbursed clinical services. Buyers now ask for enterprise contracts, standard integrations and continuous performance monitoring instead of one-off installations. Scanner manufacturers embed AI reconstruction directly into their systems, while specialist vendors extend into new modalities such as MRI and ultrasound. Government initiatives such as the US FDA's final guidance on predetermined change control plans for AI-enabled device software functions, issued in December 2024, allow manufacturers to update cleared algorithms within pre-agreed limits without filing a new submission each time. In Europe, the provisional political agreement reached in May 2026 on the Digital Omnibus moves the EU AI Act's high-risk obligations for AI embedded in regulated products such as medical devices to 2 August 2028, giving developers more time to prepare technical documentation and human-oversight controls. By Region, North America held the largest share of the market in 2025, supported by early FDA clearances, established payer coverage and a large base of enterprise hospital deployments. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by national screening programs in India, expanding domestic vendors in China and South Korea, and rising demand for low-cost diagnostic capacity.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Foundation Models and Multi-Finding Triage Emerging as a Transformational Trend

• Developers are moving from one-algorithm-per-disease products to foundation models trained on large sets of scans. A single model can screen one study for many acute findings at the same time. This lowers the cost of adding each new indication and reduces the stack of separate alerts that radiologists otherwise receive from several vendors.
• Enterprise AI platforms are becoming the delivery layer for these models. Hospitals prefer one integration, one governance dashboard and one contract instead of a dozen vendor connections. Platform owners now host third-party algorithms next to their own, so control of distribution is turning into a competitive asset for vendors of every size.
• Report drafting is the next layer being built on top of detection. Several vendors are developing systems that draft findings text from chest X-rays and CT scans for radiologist review. The FDA has stated that it will explore ways to tag devices that use foundation models, so developers are preparing for closer scrutiny of these tools.
• Aidoc received FDA clearance for a rib fracture triage tool built on its CARE1 foundation model, described by the company as the first clearance of a device powered by this technology. Aidoc states that foundation models shrink the development timeline for new indications from years to weeks.

KEY MARKET DRIVER

Rising Imaging Volumes and Radiologist Workload Pressure is the Key Driver

• Imaging demand continues to outpace the growth of the radiologist workforce in many health systems. Reading queues lengthen, especially in emergency departments and outpatient centers. AI triage moves suspected critical scans to the top of the worklist, so hospitals now buy it as a turnaround-time tool rather than as an experimental add-on.
• Emergency and trauma care show the value of a second look. Fractures and small findings on plain films are easy to miss under time pressure. Fracture detection software now carries FDA clearance for adults and for children older than two years, which gives emergency departments a validated safety net for high-volume X-ray reading.
• Scanner makers now build AI into the imaging chain itself. GE HealthCare reports that its deep-learning MRI reconstruction cuts scan time by up to 50 percent, and Philips has added AI reconstruction to its latest spectral CT. Because the software ships with the scanner, adoption follows the equipment replacement cycle and needs no separate purchase decision.
• A study published in Cureus in July 2026, based on the FDA's public list of AI-enabled devices, counted 1,430 authorizations through December 2025. Radiology accounted for 1,094 of them, or about 76 percent, and 2025 alone added 331 authorizations. The list itself is maintained on the FDA website, and the agency updates it periodically.

KEY MARKET OPPORTUNITY

Opportunistic Screening and Public Health Programs Creating New Revenue Pools

• Routine CT scans ordered for other reasons often contain unreported signs of heart, bone and liver disease. AI can flag coronary calcium, low bone density and fatty liver on those scans without extra imaging. This turns existing scan archives into a preventive-care pipeline and gives health systems new follow-up visits and treatment starts.
• Public health programs in high-burden countries need low-cost chest X-ray reading for tuberculosis and lung disease. The WHO has recommended computer-aided detection for tuberculosis screening on chest X-rays since 2021. AI acts as the reader where radiologists are scarce, which lets national programs screen at population scale and refer only flagged cases for confirmatory testing.
• Drug developers are a second buyer group. Vendors now sell imaging biomarker automation, patient identification and trial analytics to life sciences sponsors, using the same algorithms that hospitals run in daily care. This adds contract and data-licensing revenue that does not depend on hospital budgets, reimbursement decisions or annual capital cycles.
• The UK Department of Health and Social Care announced the EDITH trial, backed by about USD 13.8 million (GBP 11 million) through the NIHR. Nearly 700,000 women attending routine screening at 30 sites will be invited to join, testing whether one radiologist with AI support can replace two readers per mammogram.

AI Medical Imaging Software Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Imaging Modality

Computed tomography held the largest market share in 2025, driven by the high volume of CT examinations and the growing use of AI for time-sensitive diagnostic applications. CT generates large volumes of standardized, high-resolution imaging data that can be efficiently analyzed using AI algorithms. Stroke assessment, pulmonary embolism detection, lung nodule identification and cardiac imaging are among the major applications supporting adoption. The increasing need for rapid interpretation in emergency and acute-care settings further strengthens demand for AI-enabled CT analysis.

Ultrasound is projected to grow at the fastest CAGR during the forecast period, supported by increasing use of portable and point-of-care imaging across hospitals, clinics and emergency settings. AI can provide real-time image guidance, automated measurements and interpretation support, helping address variability in image acquisition and operator experience. Lower equipment costs, absence of ionizing radiation and expanding use in obstetrics, cardiology and primary care are expected to support wider adoption of AI-enabled ultrasound solutions.

Imaging Modality categories include

• X-ray
• Computed Tomography (Dominating Segment)
• Magnetic Resonance Imaging
• Ultrasound (Highest CAGR Segment)
• Nuclear Imaging
• Others

Analysis by Application

Neurology held the largest market share in 2025, supported by the critical role of rapid imaging assessment in stroke and other acute neurological conditions. AI can rapidly identify abnormalities such as intracranial hemorrhage, large vessel occlusion and ischemic changes, helping prioritize time-sensitive cases. Growing stroke incidence, increasing emphasis on reducing treatment delays and the availability of established imaging-based clinical pathways continue to support high adoption of AI solutions in neurology.

Oncology is projected to grow at the fastest CAGR during the forecast period, driven by increasing cancer screening volumes and the growing application of AI across detection, characterization and treatment planning. AI can assist in identifying subtle abnormalities across mammography, CT, MRI and other imaging modalities while reducing interpretation workload. Expanding screening programs, rising cancer incidence and growing demand for earlier diagnosis are expected to increase adoption of AI-based imaging solutions throughout oncology workflows.

Application categories include

• Neurology (Dominating Segment)
• Oncology (Highest CAGR Segment)
• Cardiology
• Pulmonology
• Musculoskeletal
• Others

Analysis by Deployment Mode

On-premises deployment held the largest market share in 2025, supported by healthcare organizations' requirements for data control, privacy and integration with existing imaging infrastructure. Hospitals with established IT environments often prefer processing medical images within their own networks to maintain control over sensitive patient information and ensure predictable system performance. Existing investments in PACS, servers and hospital IT infrastructure also reduce the need for immediate migration to external platforms.

Cloud-based deployment is projected to grow at the fastest CAGR during the forecast period, driven by increasing demand for scalable and remotely accessible AI solutions. Cloud deployment reduces the need for dedicated hardware and enables healthcare providers to access updated algorithms without extensive local infrastructure. It is particularly attractive to smaller hospitals, outpatient facilities and imaging networks seeking flexible implementation. Growing healthcare cloud adoption, improved connectivity and increasing acceptance of remote data processing are expected to accelerate this segment.

Deployment Mode categories include

• On-Premises (Dominating Segment)
• Cloud-Based (Highest CAGR Segment)
• Hybrid

Analysis by End User

Hospitals held the largest market share in 2025, owing to their high volume of diagnostic imaging examinations and concentration of emergency, specialized and complex-care services. Hospitals also have greater access to imaging infrastructure, clinical specialists and healthcare IT systems required to integrate AI into existing workflows. The increasing pressure to improve diagnostic turnaround times, manage radiologist workloads and support clinical decision-making further drives adoption across hospital settings.

Diagnostic imaging centers are projected to grow at the fastest CAGR during the forecast period, as outpatient groups adopt AI to handle rising screening volumes with limited radiologist capacity. Vendors are widening triage tools beyond emergency rooms into ambulatory settings, where routine scans can wait in long backlogs, as Aidoc noted with its January 2026 clearance. Outpatient centers run high-volume mammography and CT calcium scoring, which suit per-study pricing and cloud delivery. Consolidation of imaging chains and teleradiology networks lets one AI contract cover many sites, and this raises adoption faster than in single hospitals.

End User categories include

• Hospitals (Dominating Segment)
• Diagnostic Imaging Centers (Highest CAGR Segment)
• Research Institutes
• Others

By Region

North America held the largest market share in 2025, accounting for 45% of the global market. The United States leads the region due to its advanced healthcare infrastructure, high diagnostic imaging volumes, strong adoption of digital health technologies and established regulatory pathways for AI-enabled medical devices. The country's large network of hospitals and diagnostic centers, combined with increasing radiologist workloads and demand for faster diagnosis, supports widespread adoption of AI medical imaging software. Canada is also expanding digital health and AI adoption across healthcare, supported by investments in healthcare modernization and imaging infrastructure, while Mexico remains at an earlier stage with adoption concentrated in larger hospitals and private healthcare providers.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, rising from a 22% share in 2025 to about 33% by 2034. China, India, Japan, South Korea and Australia are the major markets driving regional expansion. China benefits from a large healthcare system, increasing medical imaging volumes and government support for artificial intelligence development. India is experiencing growing demand for AI-assisted screening and diagnostic services due to its large patient population and uneven distribution of radiologists. Japan and South Korea have advanced healthcare and technology infrastructure that supports integration of AI into imaging workflows, while Australia is expanding digital health adoption across hospitals and diagnostic services. Increasing healthcare expenditure, rising chronic disease prevalence and growing demand for accessible diagnostic services are expected to sustain regional growth.

Countries and Regions Covered

North America (Dominating Region)

• United States (Largest Country Market)
• Canada
• Mexico

Asia-Pacific (Fastest Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific

Europe

• Germany (Largest Country Market)
• France
• United Kingdom
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The AI Medical Imaging Software Market is fragmented. A study of the FDA's AI-enabled device list found about 740 manufacturers with authorizations, roughly 68% of them holding a single device, and only 13 companies accounting for about 17% of all authorizations. Scanner makers GE HealthCare, Siemens Healthineers and Philips lead by clearance count, while specialists such as Aidoc, Viz.ai, RapidAI, Lunit and Qure.ai compete on clinical depth and enterprise platforms. Key success factors include breadth of cleared indications, PACS and EHR integration, reimbursement access and proven turnaround-time gains. Leading companies are prioritizing foundation models, multi-modality portfolios and marketplace distribution, and they keep acquiring smaller developers to add modalities and regional access.

Key Players

• GE HealthCare Technologies Inc. (US)
• Siemens Healthineers AG (Germany)
• Koninklijke Philips N.V. (Netherlands)
• Aidoc Medical Ltd. (Israel)
• Viz.ai, Inc. (US)
• RapidAI (US)
• Lunit Inc. (South Korea)
• Qure.ai (India)
• Heartflow, Inc. (US)
• DeepHealth, Inc. (US)
• Harrison.ai (Australia)
• Cleerly, Inc. (US)
• Brainomix Limited (UK)
• Nano-X Imaging Ltd. (Israel)

Recent Market Developments

• In March 2025, Gleamer, the French radiology AI company, acquired Pixyl, a developer of FDA- and CE-cleared neuro MRI applications, and Caerus Medical, a developer of lumbar MRI AI software. The deals added MRI to Gleamer's X-ray, mammography and CT portfolio and give hospitals one proprietary supplier across all core modalities, signaling a wider push by AI vendors into MRI.
• In January 2026, Aetna began covering Cleerly LABS coronary plaque analysis, joining UnitedHealthcare, Cigna and Humana. Cleerly reports that commercial payors covering more than 86 million Americans now support AI-enabled coronary plaque analysis, which widens reimbursed access to AI-based cardiac CT analysis in the United States.
• In February 2026, Qure.ai received FDA 510(k) clearance for qXR-Detect, a computer-assisted detection solution for chest X-rays that adds six new indications and takes its total FDA-cleared indications to 26. The clearance strengthens the company's US expansion in a segment where about 70 million chest radiographs are taken each year in emergency, outpatient and routine care.
• In March 2026, GE HealthCare completed its acquisition of Intelerad for a base purchase price of USD 2.3 billion in cash. Intelerad's cloud PACS and enterprise imaging software extend GE HealthCare's AI and imaging portfolio into ambulatory care, teleradiology and specialized clinics, and the deal signals a shift toward cloud-first, AI-enabled enterprise imaging platforms.

Frequently Asked Questions